Sean M Mccarthy

US Patent:

7057017, Jun 6, 2006

Filed:

Oct 4, 2001

Appl. No.:

09/972473

Inventors:

Sean A. McCarthy - San Diego CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 14/47
C07K 14/475
C07K 19/00

US Classification:

530350, 530300, 530324, 530866

Abstract:

Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7446181, Nov 4, 2008

Filed:

Apr 6, 2004

Appl. No.:

10/819054

Inventors:

Sean A. McCarthy - San Diego CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 16/24

US Classification:

53038823, 5303873, 5303881, 53038815, 5303891, 5303892, 5303913, 530866

Abstract:

The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions.

US Patent:

7579168, Aug 25, 2009

Filed:

Oct 21, 2005

Appl. No.:

11/255790

Inventors:

Sean A McCarthy - San Diego CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12P 21/02
C12N 15/63
C12N 15/74
C12N 15/79
C12N 15/81
C12N 15/86
C12N 1/21
C12N 1/19
C12N 5/10
C12N 15/12
C12N 15/62
C07H 21/04
C07K 14/47
C07K 19/00

US Classification:

435 691, 4352523, 4352542, 4353201, 435325, 435348, 530350, 536 234, 536 235, 536 241

Abstract:

Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7645451, Jan 12, 2010

Filed:

Feb 28, 2005

Appl. No.:

11/069137

Inventors:

Sean A. McCarthy - San Diego CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/18
C07K 16/46

US Classification:

4241421, 424 149, 4241331, 4241781, 5303873, 53038815, 530866, 530867

Abstract:

Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and n which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

7897725, Mar 1, 2011

Filed:

Oct 12, 2007

Appl. No.:

11/974478

Inventors:

Sean A. McCarthy - San Diego CA, US
David P. Gearing - Camberwell, AU

International Classification:

C07K 1/00
C07H 21/04
C12N 15/85
C12N 15/63

US Classification:

530350, 435326, 4353201, 4352523, 43525411, 536 235

Abstract:

The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

8202966, Jun 19, 2012

Filed:

Nov 12, 2009

Appl. No.:

12/616901

Inventors:

Sean A. McCarthy - San Diego CA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07K 14/475
C07K 19/00
G01N 33/53

US Classification:

530300, 530350, 435 72

Abstract:

Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

20020112251, Aug 15, 2002

Filed:

Mar 9, 2001

Appl. No.:

09/803589

Inventors:

Sean McCarthy - San Diego CA, US
Douglas Holtzman - Jamaica Plain MA, US
Andrew Goodearl - Natick MA, US

International Classification:

A01K067/00
C07H021/04
C12P021/02
C12N005/06
C07K014/705

US Classification:

800/008000, 530/350000, 536/023500, 435/069100, 435/325000, 435/320100

Abstract:

The invention relates to Tango-71, Tango-79, and Tango-81 polypeptides, nucleic acid molecules encoding Tango-71, Tango-79, and Tango-81, and uses thereof. The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

US Patent:

20020150988, Oct 17, 2002

Filed:

Mar 25, 2002

Appl. No.:

10/105934

Inventors:

Sean McCarthy - San Diego CA, US
Douglas Holtzman - Jamaica Plain MA, US

Assignee:

Millennium Pharmaceuticals, Inc., a Delaware corporation

International Classification:

C12P021/02
C12N005/06
C07H021/04
C07K014/435

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023200

Abstract:

Novel FTHMA-070 and T85 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length FTHMA-070 and T85 proteins, the invention further provides isolated FTHMA-070 and T85 fusion proteins, antigenic peptides and anti-FTHMA-070 and anti-T85 antibodies. The invention also provides FTHMA-070 and T85 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a FTHMA-070 gene or T85 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.